Comment: Supporting a sustainable biosimilar solution

Highlights from ESMO 2019

Holistic management of patients with ALK-positive NSCLC

Role of molecular diagnostics in prostate cancer

Real-world use of carfilzomib in relapsed multiple myeloma patients with pre-existing cardiovascular comorbidities

Practical considerations for introducing biosimilars

Successful implementation of biosimilars through effective communication

How real-world data generation can assist biosimilar implementation

Regulatory principles for biosimilar medicines

The science of biosimilarity: Immunogenicity

Introduction of the biosimilar trastuzumab and its impact on patients and services

Practical guidance on the assessment of biosimilar monoclonal antibodies: A physician's perspective